NUR 416 Lecture Notes - Lecture 11: Infantile Hemangioma, Hemangioma, Timolol
23 Apr 2020
School
Department
Course
Professor
Document Summary
Most common pediatric vascular tumors: 5% of infants in the us. Increased incidence: prematurity, twins, family hx. Proliferation phase: grow out of proportion to growth of the infant, for up to 9 mos of age. Involution phase: complete involution in 50% by age 5 yrs, 70% by age 7 yrs. Us fda-approved in adults to tx open-angle glaucoma or ocular htn when used ophthalmically. Potent ocular hypotensive agent: reduces iop by about 25-33% in pts with elevated iop. Blocks stimulation of beta 1 (myocardial) & beta 2 (pulmonary, vascular, & uterine) adrenergic receptor sites. Therapeutic effects: decreased hr & bp, suppression of arrhythmias, prevention of mi. Moa is unclear but hypothesized: vasoconstriction, decreased renin production, inhibition of angiogenesis, stimulation of apoptosis. Monitoring is necessary for: bradycardia & hypotension, hypoglycemia, bronchospasm, hyperkalemia. Contraindications: cardiogenic shock, sinus bradycardia, hypotension, >first degree heart block, hf, bronchial asthma, hypersensitivity.
